trending Market Intelligence /marketintelligence/en/news-insights/trending/hwqB7M_vIMV_jZVCs1JCdA2 content esgSubNav
In This List

CSPC Pharmaceutical to commercialize cancer drug in US

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


CSPC Pharmaceutical to commercialize cancer drug in US

CSPC Pharmaceutical Group Ltd. engaged Casper Pharma Ltd. to develop and commercialize its oncology drug in the U.S.

Casper Pharma will conduct clinical studies and apply for regulatory approvals for the drug which will be manufactured and exclusively distributed by the company in the U.S.

CSPC will receive about $101 million in milestone-related payments in addition to a royalty on sales once the drug is launched.

The treatment is already being marketed in China.